Affimed N.V. (NASDAQ:AFMD) Shorted Shares Decreased By 17.93%

April 17, 2018 - By reb123z

The stock of Affimed N.V. (NASDAQ:AFMD) registered a decrease of 17.93% in short interest. AFMD’s total short interest was 397,800 shares in April as published by FINRA. Its down 17.93% from 484,700 shares, reported previously. With 393,700 shares average volume, it will take short sellers 1 days to cover their AFMD’s short positions. The short interest to Affimed N.V.’s float is 1.57%.

It closed at $2.1 lastly. It is down 25.96% since April 17, 2017 and is downtrending. It has underperformed by 37.51% the S&P500.

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in Germany and internationally. The company has market cap of $131.02 million. The Company’s lead candidate is AFM13, a natural killer cell TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. It currently has negative earnings. The companyÂ’s product candidates include AFM24, a NK-cell that treats epidermal growth factor receptor expressing solid tumors, such as lung, head, neck, and colon cancers; AFM26, which binds to B-cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.